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Abstract
Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate
and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate. PubMed and Web of Science
were searched for phase II and phase III randomized clinical trials with monoclonal antibodies targeting key
mediators of type 2-associated asthma. Thirty trials were selected involving biologics that target the IL-5 pathway,
IL-13, the common IL-4 and IL-13 receptor, IL-9, IL-2 and TSLP. As no head-to-head trials were retrieved from
literature, we performed an arm-based network meta-analysis to compare effects on exacerbation rate between
the different treatments.
Mepolizumab, reslizumab and benralizumab significantly reduced the risk of exacerbations compared to placebo
(by 47–52%, 50–60%, and 28–51% respectively). Reslizumab and benralizumab also improved lung function.
Dupilumab and tezepelumab improved lung function in frequent exacerbators. Lebrikizumab had no significant
effect on the number of exacerbations, symptom control or health-related quality of life. Tralokinumab improved
lung function compared to placebo. Network meta-analysis of all treatment and placebo arms, showed no superiority
of one biologic over the others. Large reductions in exacerbation rates were observed compared to placebo, though
only benralizumab was sufficiently powered (n = 2051) to demonstrate significantly decreased exacerbation rates in the
subgroup analysis of IL-5 acting agents compared to placebo.
Monoclonal antibodies such as mepolizumab, reslizumab and benralizumab have proven their benefit to reduce
exacerbation rates in severe persistent eosinophilic asthma in the published trials. However, no statistically significant
superiority was observed of one biologic over the other in the network meta-analysis. More studies with direct head to
head comparisons and better defined endotypes are required.
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Introduction
The Global Initiative of Asthma (GINA), defines asthma
as a disorder of lower airways, usually associated with
chronic airway inflammation characterized by episodic
respiratory symptoms such as wheeze, shortness of breath,
chest tightness and cough, together with variable expiratory
airflow obstruction [1]. Asthma is an overarching term for
a heterogeneous disease including multiple underlying
disease mechanisms with common clinical symptoms [2].
The estimated global prevalence of clinical asthma in adults
is 4.5%, translating into over 300 million people worldwide
with asthma. The prevalence is higher in developed coun-
tries, up to 21.5% [3].
The severity of the asthma symptoms and airflow limi-
tation typically varies over time. Symptoms often worsen
at night or early in the morning. Fluctuations can be
caused by specific triggers such as allergens, as well as
non-specific triggers such as exercise, laughter, irritant
exposure, cold air and viral infections. Conversely, asthma
symptoms can disappear spontaneously for weeks or
months. Life-threatening exacerbations, defined as acute
episodic flare-ups are the most important complications
of the disease, affecting morbidity and mortality [1].
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Asthma-phenotypes can be categorized based on clinical
characteristics or environmental triggers. This approach
evolved towards defining subtypes by different underlying
biology, also called ‘endotypes’ [2, 4]. Based on this patho-
biology-stratified approach, asthma patients can be subdi-
vided into two main categories: patients with type 2
asthma and patients with non-type 2 asthma [5]. Eosino-
philic inflammation is the hallmark symptom of type 2
asthma [2]. Blood or sputum eosinophilia are associated
with a higher risk of severe asthma exacerbations [6]. The
most important differentiating factors between the differ-
ent subendotypes are age at disease onset and atopy [7].
Treatment goals in asthma include symptom control
and reducing risk of future exacerbations. However,
approximately 3 to 5% of asthmatic patients have severe
asthma where either symptoms persist or numerous
exacerbations occur despite maximal treatment, an esti-
mate that varies by country and may reach ≥10% in the
United States [8, 9]. Therefore, an alternative approach
is required, guided by the underlying inflammatory path-
way or endotype [10]. According to the GINA pocket
guide for the management of difficult-to-treat and severe
asthma, type 2 inflammation should be considered if any
of the following are found in a patient taking high-dose
inhaled corticosteroids (ICS): elevated blood eosinophils
(≥150/μL), elevated sputum eosinophils (≥2%), elevated
FeNO (≥20 ppb) or asthma that is clinically allergen-
driven [10].
TH2-high asthmatics have an overall favorable therapy
response to ICS [11]. Nevertheless, a notable subgroup
of those patients may require higher doses, oral corticoste-
roids or have persistent symptoms despite regular cortico-
steroid use [12]. Therefore, several monoclonal antibodies
targeting specific inflammatory pathways have been devel-
oped to tackle this issue [11]. Blocking TSLP, CCR3, IL-5,
PGD2, IL-4, IL-13, IL-9 and/or IgE may be effective in the
treatment of allergic eosinophilic asthma [13–21].
This systematic review aimed to investigate the
endotype-guided asthma treatment possibilities by
monoclonal antibodies, focusing on the key drivers of
eosinophilic inflammation in type 2-associated adult
asthmatics. We aimed to provide a clear overview of
the currently available or emerging monoclonal anti-
bodies in asthma. We subsequently compared the re-
sults from different trials to evaluate the effects of
monoclonal antibodies on the median exacerbation
rate.
Methods
We conducted this review according to a predefined
protocol compliant with the PRISMA guidelines for sys-
tematic reviews [22]. The protocol registration was per-
formed using the PROSPERO international prospective
register of systematic reviews. (Registration number:
CRD42019127706) A structured search strategy of
PubMed and Web of Science was developed to identify
all phase II and III clinical trials published in English, in-
vestigating the treatment of type 2 asthma using mono-
clonal antibodies between 2005 and 2018. Studies
conducted on small sample sizes (50 or less), post-hoc
studies, open label extensions and studies taking gluco-
corticoid sparing effect as primary endpoint were ex-
cluded [23–26]. Conference or poster abstracts and
studies not conducted on humans were also excluded.
These exclusions aimed to ensure adequate power,
homogeneity and clinical relevance among included
studies. Studies conducted on omalizumab, an immuno-
globulin E neutralizing agent, were excluded, as it is cur-
rently a well-known and established therapeutic target,
and an excellent Cochrane systematic review discussing
its use in adult and children has already been published
[27]. Search results were reviewed independently by two
investigators (AE and SDF) to determine the eligibility of
potential studies, results were compared and disagree-
ment was resolved to create the final list of included
studies by the involvement of a third researcher (LL).
Risk of bias was assessed using the Cochrane risk of bias
tool for randomized controlled trials [28]. This tool as-
sesses studies based on six criteria including: random
sequence generation, allocation concealment, selective
reporting, blinding, incomplete outcome data and a cat-
egory for any other perceived type of bias [28]. The
search terms used in both databases and details on data
extraction strategy are included in the Additional file 1:
online supplement.
Statistical analysis
Arm-based patient centered network meta-analysis was
conducted using the pcnetmeta package in R statistical
software. With no head to head trials available, arm-based
network meta-analysis estimates the comparative effect for
multiple interventions based on their pooled effects from
the included studies [29–32]. Specific details regarding the
analysis methods are outlined in the Additional file 1:
online supplement.
Results
We initially identified 1110 records, after removal of
duplicates, 651 articles remained. 84 articles were eli-
gible for abstract review based on title, subsequently 39
articles were selected for full text review based on ab-
stract. Thirty records were included in the systematic
review. A flow diagram of the selection procedure is
represented in Fig. 1. Results focus on exacerbations for
which 13 records were included in the meta-analysis
[13, 15, 19, 33–42]. Additional results on lung function,
quality of life and safety are outlined in the Additional
file 1: online supplement.
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Risk of Bias
The included studies had a limited risk of bias (Table 1).
Fifteen (50%) of the included studies had a low risk of
bias, 9 studies (30%) had a moderate risk of bias and 6
studies (20%) had a high risk of bias. High or moderate
risk of bias was mainly due to unreported randomization
(n = 6), allocation concealment (n = 13) or blinding tech-
niques (n = 7). All trials except one were industry
funded, this was regarded as an unclear potential of bias,
considered higher if company staff were involved in trial
design or data analysis [43–45]. One trial was deemed to
have a high risk of bias in their reporting [46].
Targeting interleukin-5
IL-5 is a key factor in the maturation and maintenance
of eosinophils, potentially representing an interesting
treatment target. Risk of exacerbations may be reduced
by eosinophil elimination in inflammatory tissues and
blood (Additional file 1: Table S1) [6, 47]. Several monoclo-
nal antibodies acting on the pathway have been investigated
and three agents have already received FDA and EMA
approval for use in eosinophilic asthma (mepolizumab,
benralizumab and reslizumab). The mechanisms of action
of IL-5 agents are illustrated in Fig. 2.
Mepolizumab
Mepolizumab binds to soluble IL-5 inhibiting its inter-
action with its eosinophil surface receptor. It can be ad-
ministered intravenously (IV) or subcutaneously (SC)
[15, 36, 48–50]. Mepolizumab efficacy has been investi-
gated in 5 trials. Patients who had at least 2 exacerbations
in the previous year despite receiving high-dosage ICS
were included in all trials, four trials required subjects to
also have elevated blood eosinophil counts of ≥300 cells/
μL or sputum eosinophil counts ≥3% [15, 36, 48–50]. IL-
5, eosinophilia and exacerbations are closely linked, there-
fore, the effect of mepolizumab on yearly exacerbation
rates has been extensively studied. Exacerbation risk was
reduced compared to placebo by 53% for SC mepolizumab
and 47 to 48% for low dose, 39% for medium dose and 49
to 52% for high dose IV mepolizumab [15, 36, 49]. Chupp
et al. also reported a statistically significant reduction in
clinically significant exacerbations (RR: 0.32, CI: 0.31–
0.56) [48]. Flood-Page et al. report a non-statistically
Fig. 1 Search through PubMed and Web of Science: flow chart. Flowchart of the search and selection procedure. Of 651 initial records (after
duplicate removal) initially retrieved with our search strategy, 567 studies met our exclusion criteria based on title, and 45 based on abstracts.
A full text review was performed for the remaining 39 studies, and nine were excluded
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significant trend towards decreased exacerbation rate with
a high dose of 750mg IV, but their study did not select
patients based on number of exacerbations [50]. Results
about the reduction in severe exacerbations (defined as
requiring hospitalization or emergency department visit)
were less consistent [15, 36, 48, 49]. For example, Chupp
et al. reported a significant reduction in exacerbations
requiring admission to a hospital or ER visit, while the
reduction in exacerbations requiring admissions as a
single end-point was not significant [48]. Conversely,
Ortega et al. reported reductions in both outcomes did
not reach statistical significance [36].
Reslizumab
Reslizumab is administered IV, it binds to IL-5 selectively
downregulating its pathway [51]. Reslizumab’s efficacy was
investigated by four trials on different patient populations.
Castro et al., in a phase III trial, only included patients with
uncontrolled asthma who had at least 1 exacerbation in the
previous year despite treatment with medium or high dose
ICS and with blood eosinophil counts ≥400 cells/μL [37].
Two phase III trials did not take exacerbation history into
account and differed in their inclusion of patients with
lower blood eosinophil counts [52, 53]. An older phase II
trial by Castro et al. had high dose ICS and sputum
Table 1 Risk of Bias for all studies included in the systematic review
Study (Ref) Random Sequence
Generation
Allocation
Concealment
Selective Reporting Other Bias Blinding Incomplete
outcome data
BIAS judgement
Flood-Page et al. 2007 [50] Unclear Unclear Low High Unclear Low High Risk
Busse et al. 2008 [68] Unclear Unclear Low Unclear Low Low High Risk
Haldar et al. 2009 [49] Low Unclear Low Unclear Unclear Low Intermediate Risk
Corren et al. 2011 [18] Low Low Low Unclear Low Low Low Risk
Castro et al. 2011 [54] Unclear Unclear Low Unclear Low Low Intermediate Risk
Pavord et al. 2012 [15] Low Low Low Unclear Low Low Low Risk
Noonan et al. 2013 [57] Unclear Unclear Low Unclear Unclear Low High Risk
Wenzel et al. 2013 [65] Low Low Low Unclear Low Low Low Risk
Oh et al. 2013 [20] Low Low Unclear Unclear Low Unclear Low Risk
Piper et al. 2013 [59] Low Unclear Low Unclear Unclear Low Intermediate Risk
De Boever et al. 2014 [62] Low Low Low Unclear Low Low Low Risk
Ortega et al. 2014 [36] Low Unclear Low Unclear Low Unclear Intermediate Risk
Castro et al. 2014 [42] Low Low Low Unclear Low Low Low Risk
Hanania et al. 2015 [33] Low Low Unclear Unclear Low Low Intermediate Risk
Brightling et al. 2015 [61] Low Low Low Unclear Unclear Low Intermediate Risk
Castro et al. 2015 [37] Low Low Low Unclear Low Low Low Risk
Hanania et al. 2016 [34] Low Low Low Unclear Low Low Low Risk
Bjermer et al. 2016 [53] Unclear Unclear Unclear Unclear Unclear Unclear High Risk
Corren et al. 2016 [52] Unclear Unclear Low Unclear Unclear Low High Risk
Bleecker et al. 2016 [38] Low Unclear Low Unclear Low Low Intermediate Risk
FitzGerald et al. 2016 [39] Low Low Low Unclear Low Low Low Risk
Park et al. 2016 [40] Low Unclear Low Low Low Low Low Risk
Nowak et al. 2016 [41] Low Unclear Low Unclear Low Low Intermediate Risk
Wenzel et al. 2016 [64] Low Low Low Unclear Low Low Low Risk
Corren et al. 2017 [13] Low Low Low Unclear Low Low Low Risk
Chupp et al. 2017 [48] Low Low Low Unclear Low Low Low Risk
Ferguson et al. 2017 [46] Low Low Low Unclear Low High Intermediate Risk
Panettieri et al. 2018 [35] Low Low Low Unclear Low Low Low Risk
Russel et al. 2018 [60] Low Low Low Unclear Low Low Low Risk
Castro et al. 2018 [19] Low Unclear Low High Low Low High Risk
Risk of bias assessed by Cochrane tool for randomized controlled trials. Thirty studies were assessed for their risk of bias. Underlined studies are included in
the meta-analysis
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eosinophil counts ≥3% as main inclusion criteria [54].
Therefore, it is difficult to compare the four trial results. In
our review, we included patients who received IV reslizu-
mab 3.0 mg/kg every 4 weeks, as the 0.3 mg/kg proved
less efficient [37, 52–54]. Castro et al., confirmed the
beneficial effect of eosinophil reduction on exacerba-
tion rates, exacerbation risk was reduced by 50–60%
compared to placebo in the selected asthma population
[37]. Reslizumab also delayed the time to the first ex-
acerbation. A statistically non-significant decrease in
hospital admissions or emergency department visits by
asthma exacerbations was reported [37].
Benralizumab
In contrast to reslizumab and mepolizumab, benralizumab
binds the interleukin-5 receptor α (IL-5Rα) expressed on
eosinophil surfaces, as well as FcγIIIRa receptors located
on natural killer cells leading to eosinophil apoptosis [55].
Benralizumab is usually administered SC. Efficacy has
been investigated by two phase II [40, 41] and four phase
Fig. 2 Mechanism of action of agents included in the meta-analysis. Mechanisms of action of monoclonal antibodies included in our meta-analysis (a)
IL-5 is a critical factor for growth, differentiation and activation of eosinophils. Mepolizumab and reslizumab act as antibodies to IL-5 cytokines, binding
to them and preventing their association with the receptor. Benralizumab is an IL-5 receptor blocker. It binds to the alpha chain of the IL-5 receptor
(IL-5Rα), expressed on eosinophils. The antibody’s Fc domain binds to the FcγRIIIa domain, expressed on natural killer cells, which induces eosinophils’
apoptosis. b TSLP is an important cytokine in the inflammatory cascade, as it activates dendritic cells, inducing inflammatory reactions through their
effects on T cells differentiation. Tezepelumab inhibits TSLP effects by binding to the cytokine. IL-4 is a potent inducer for TH2 cells differentiation,
existing on several types of immune cells. Dupilumab binds to the alpha subunit of IL-4 receptor, inhibiting its effects. Lebrikizumab binds to IL-13
cytokines, and tralokinumab binds to its receptor on B cells, inhibiting its effects on IgE production
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III trials [38, 39, 42, 46]. Phase III trials selected pa-
tients with uncontrolled asthma who had at least 2
exacerbations in the previous year despite receiving
high dose ICS + LABA and with blood eosinophil counts
≥300 cells/μL [38, 39, 42, 46].
The reduced eosinophil counts by benralizumab treat-
ment improved exacerbation rates. According to the
SIROCCO and the CALIMA-trial, risk of exacerbations
was 36 to 45% lower compared to placebo when 30 mg
benralizumab was administered every 4 weeks (Q4W)
and 28 to 51% lower when benralizumab is administered
every 8 weeks (Q8W). Patients who had 3 exacerbations
or more in the previous year had most benefit from ben-
ralizumab treatment [38, 39]. Park et al. demonstrated a
reduction in exacerbation rates compared to placebo of
33, 36 and 45% by 2mg, 20 mg and 100 mg of benralizu-
mab treatment every 4 weeks (every 8 weeks after first
three doses), respectively [40]. Castro et al. also showed
reduced exacerbation rates in the 100mg dose groups vs
placebo (0·34 vs 0·57) using the same dosing intervals
[42]. Moreover, benralizumab reduced the risk of onset
of exacerbation by 37 to 39% in the Q4W-arm and by 27
to 40% in the Q8W-arm [38, 40]. Inconsistent data was re-
ported about benralizumab reducing exacerbation-related
emergency department visits or hospital admissions com-
pared to placebo [38, 39]. One investigation was designed
to discover the potential to reduce future exacerbations by
giving benralizumab IV during an acute exacerbation at
the emergency department. The number of patients who
experienced a second exacerbation within 12 weeks after
the first was not reduced. However, the exacerbation rates
and the number of exacerbation-related hospitalizations
were 49 and 60% lower, respectively [41].
Targeting interleukin-13
IL-13 may be the driver of goblet cell hyperplasia and
smooth muscle contractility in type 2-associated asthma.
Moreover, IL-13 is one of the two crucial cytokines in
the isotype switch of B cells towards IgE in allergic
asthma. Therefore, IL-13 may be a potential therapeutic
target in the treatment of asthma (Additional file 1:
Table S2) [47, 56].
Lebrikizumab
Lebrikizumab, administered SC, potentially improves lung
function and symptom control in asthma by binding to
IL-13, neutralizing its functional activities [18, 33, 34, 57].
Lebrikizumab’s efficacy has been investigated by three
phase II and one phase III trials. Patients were included
based on their maintenance ICS: low to high dose [18],
medium to high dose (LUTE and VERSE-trials) [33], or
no glucocorticoids at all [57]. The combined LUTE and
VERSE-trials were originally set up to be phase III, how-
ever, an identified host cell protein impurity led to early
termination of dosing and the protocol was amended as a
phase II trial [33]. LAVOLTA I and LAVOLTA II were the
only phase III trials to investigate lebrikizumab, eligible
patients were aged 18–75 years with uncontrolled asthma,
pre-bronchodilator FEV1 40–80% predicted, bronchodila-
tor response of at least 12%, and on stable background
therapy with inhaled corticosteroids for at least 6months
and at least one additional controller medication [34].
Lebrikizumab effect on exacerbation rate was incon-
sistent amongst the trials, The LUTE and VERSE repli-
cate trials show significant reduced risk on exacerbations
compared to placebo in the periostin-high group of pa-
tients treated with 37.5 mg (81% reduction) or 125mg
lebrikizumab (77% reduction). No significant reduced
exacerbation rates are observed in periostin-high pa-
tients treated with lebrikizumab 250 mg and serum peri-
ostin-low patients irrespective of dose [33]. No
consistent significant effect of lebrikizumab on exacerba-
tion rates was reported in LAVOLTA I and LAVOLTA II
phase III [34].
Tralokinumab
Tralokinumab inhibits downstream IL-13 mediated ef-
fects by preventing IL-13 binding to both IL-13Rα1 and
IL-13Rα2, considered important mediators of fibrosis
[58]. It is administered SC. Its efficacy was investigated
in 3 phase II trials selecting patients with uncontrolled
asthma who had at least one [59], three [60] or 2 to six
exacerbations in the previous year [61]. Tralokinumab
was also tested in STRATOS I and STRATOS II phase
III trials that enrolled patients 12–75 years with a history
of asthma for at least one year and requiring medium to
high dose ICS and a LABA for at least 3 months before
enrollment [35].
The primary outcome of the first phase II trial was the
change in ACQ-6 after 13 weeks tralokinumab treat-
ment. None of the administered doses improved symp-
tom control compared to placebo [59]. Furthermore,
none of the secondary outcomes (FEV1, FVC, PEF, exac-
erbations and AQLQ) significantly improved compared
to placebo. The only exception was the improved pre-
bronchodilator FEV1 compared to placebo by 600 mg
tralokinumab treatment (0.20 L) that just reached signifi-
cance [59]. Tralokinumab lack of clinical efficacy is
further confirmed by the 2015 phase IIb randomized
trial [61] as well as the recent 2018 STRATOS I and
STRATOS II phase III trials, which showed inconsistent
effects on exacerbation rate [35]. MESOS trial also
showed no effect on bronchial eosinophilic count [60].
GSK679586
GSK679586 also binds and neutralizes IL-13 and is ad-
ministered IV. The efficacy of GSK679586 is investigated
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by a phase II trial selecting patients with uncontrolled
asthma despite receiving a high dose ICS [62].
The primary outcome was change in ACQ-7 after
12 weeks of therapy. No significant improvements in
symptom control were demonstrated, even with in-
creased serum IgE levels or elevated blood eosinophil
counts [62]. GSK679586 did not result in statistically
significant improvements in FEV1 [62]. Likewise,
GSK679586 had no effects on exacerbations compared
to placebo [62]. IgE levels in the intervention group
remained generally unchanged during the treatment.
Blood eosinophil counts where slightly higher com-
pared to placebo because of a downward trend in eo-
sinophil counts in the placebo group [62].
Targeting both interleukin-4 and interleukin-13
IL-4 and IL-13 share a common receptor, IL-4Rα, an in-
teresting therapeutic target: both powerful mediators of
type 2 immunity are targeted by only one intervention.
T-cell differentiation to the TH2-subtype, the isotype
switch towards IgE and effects on goblet cell hyperplasia
and smooth muscle contractility are prevented by block-
ing IL-4 and IL-13 simultaneously, which may result in
improved asthma outcomes [47, 56, 63].
Dupilumab
Dupilumab is an anti-IL-4Rα antibody approved which
binds to IL-4 type 1 receptor and is SC administered
[19, 64, 65]. Dupilumab was recently approved by the
FDA as an add-on maintenance therapy in moderate to
severe asthma [66]. The efficacy of dupilumab treatment
is mostly substantiated by a large-scale phase III trial
(LIBERTY ASTHMA QUEST) for patients with uncon-
trolled asthma who had at least 1 exacerbation in the
previous year despite treatment with high dose of ICS
(Additional file 1: Table S3) [19]. Two older phase II tri-
als primarily analyzed patients receiving medium-to high
dose ICS + LABA and with blood eosinophil counts
≥300 cells/μL or sputum eosinophil counts ≥3% [64, 65].
The number of exacerbations is significantly reduced
by 46.9 to 70.5% when dupilumab 200mg or 300 mg is
administered every two weeks, irrespective of eosinophil
levels. The eosinophil-high patients and the FeNO-high
patients showed better responses [19, 64]. Patients with
blood eosinophil levels < 150/μL had exacerbation rates
similar to those treated with placebo [19]. Weekly dupi-
lumab administration resulted in an 87% reduction of
asthma events [65]. The administration interval of 4
weeks turns out to be less advantageous, with small or
non-significant reductions in annualized exacerbation
rates [64]. In the overall population, dupilumab given
every 2 weeks reduced exacerbation-related hospitalization
or emergency department visit with 46.8% [19] and de-
layed the time to first exacerbation [64].
Targeting interleukin-9
IL-9 is believed to have a mediating role in the patho-
genesis of allergic asthma, especially in the mast cell
component. Therefore, targeting IL-9 may be interesting
in the hunt for newer and more specific asthma treat-
ment strategies [47, 56].
MEDI-528
MEDI-528 targets IL-9 aiming to inhibit its function in
the asthma pathogenesis. MEDI-528 is administered SC.
A phase II trial investigated efficacy in patients with un-
controlled asthma who had at least 1 exacerbation in the
previous year (Additional file 1: Table S4) [20].
The primary outcome, ACQ-6 at week 13 was not sig-
nificantly affected by MEDI-528 treatment. Post-hoc
analyses in subgroups stratifying patients based on
atopy, ICS dose or peripheral blood eosinophil counts,
showed no significant outcome. Likewise, no secondary
outcomes were significantly improved: prebronchodila-
tor FEV1, annualized exacerbation rate and AQLQ(S)-
score [20].
Targeting thymic stromal lymphopoietin
TSLP is one of the key drivers of the asthmatic pathophysi-
ology as it is produced by the airway epithelium in response
to inhaled allergens and proinflammatory stressors. Target-
ing TSLP may be interesting because of its upstream role in
the asthma cascade [47, 67].
Tezepelumab
Tezepelumab binds to TSLP, inhibiting its stimulating
activity on dendritic cells and innate lymphoid cells thus
preventing the induction of type 2 cytokines (e.g.: IL-5,
IL-4 and IL-13). It is administered SC. It has been inves-
tigated by a phase II trial in patients with uncontrolled
asthma and multiple exacerbations in the previous year
despite receiving medium to high dose ICS (Additional
file 1: Table S5) [13]. The exacerbation risk was signifi-
cantly reduced in tezepelumab groups - irrespective of
the baseline blood eosinophil count - compared to pla-
cebo by 62% in the low-dose group, 71% in the medium-
dose group and 66% in the high-dose group.
Daclizumab
Daclizumab works by binding to the IL-2R α chain
(CD25) thereby inhibiting lymphocyte activation. Only one
RCT was retrieved from the literature for Daclizumab
(Additional file 1: Table S6). Busse et al., in 2008, tested the
efficacy of Daclizumab in 115 patients assessed by the
change in FEV1 in moderate to severe uncontrolled asthma
[68]. Improvements were noted for the intervention group
(88 patients) (4.4 ± 1.80% vs 1.5 ± 2.39%; p = 0.05), daytime
asthma symptoms were reduced (p = 0.018), and time to
exacerbation was prolonged (p = 0.024). FEV1 absolute
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increase (L) in the treated group ranged from 2.34 ± 0.07
(baseline) to 2.4 ± 0.08 (Day 84), while patients receiving
placebo had a decrease in FEV1 from 2.25 ± 0.1 to 2.2 ± 0.1
L. [68]. The trial reported an increase in serious adverse
events in the treatment arm (5 vs 1) [68].
Network meta-analysis
A network meta-analysis was performed to evaluate
effect differences of the monoclonal antibodies on annu-
alized exacerbation rates. All trials on the seven mono-
clonal antibodies having exacerbation rate as a primary
outcome were added to the meta-analysis. Mepolizumab
and benralizumab were the most investigated in the
included studies. None of the included monoclonal anti-
bodies demonstrated statistically significant effect differ-
ences on the exacerbations rate compared to placebo.
(Table 2) In addition, the network meta-analysis revealed
no superiority of any included biological on exacerbation
rate in the indirect head to head comparisons. (Table 2)
Percentage of studies with low risk of bias included for
every drug is outlined in Table 3. The summary of effect
sizes and confidence intervals shown in Additional file 1:
Fig. S1 demonstrates the highest median exacerbation
rate among the pooled placebo group and the lowest
among the tezepelumab-treated arms. However, the
effect estimate of the tezepelumab-treated arm had also
the widest surrounding confidence interval highlighting
the high uncertainty on the estimate itself and indicating
the lack of power to support significant improvement
compared to placebo. A downward trend in the exacer-
bation rate by study year (between 2012 and 2018) was
observed. Sub-group analyses were conducted based on
the mechanism of action. The pooled placebo group of
the seven studies with drugs acting on the IL-5 pathway
(mepolizumab, benralizumab and reslizumab) had a
higher mean exacerbation rate compared to the pooled
placebo group of trials conducted with other agents.
(Figs. 3 and 4) Only the benralizumab arm was suffi-
ciently powered (n = 2051) to demonstrate a significantly
decreased exacerbation rate of − 0.730 (95% confidence
interval − 1.490, − 0.051) compared to placebo in this sub-
group analysis. In the second subgroup (not acting on IL-
5 pathway), no single agent was sufficiently powered to
show significant superiority compared to placebo.
Discussion
We retrieved a total of 30 randomized placebo-controlled
clinical trials investigating the efficacy of these biologics. All
trials were conducted between 2007 and 2018. Most trials
(29/30) were industry sponsored, resulting in possible bias.
Only 50% of the trials were deemed to be of a low-risk of
bias, while 6 were assessed to be at an increased risk. The
trials mostly included patients with moderate to severe
asthma proven by a history of exacerbations or based on
blood eosinophils level. Most trials used either exacerbation
rates, FEV1 change or symptom scoring as a primary end-
point. Mepolizumab, reslizumab and benralizumab have all
been shown to reduce exacerbation rates for patients with
moderate to severe asthma [15, 36–38, 42, 69]. Most trials
included patients based on their history of exacerbations
and blood eosinophilia. Reduction in exacerbation rates
ranged from 40% (benralizumab) to 60% (reslizumab). Ef-
fects on quality of life varied by agent, study design and
drug dose. These results show the potential clinical effects
of blocking the IL-5 pathway in moderate to severe asthma.
In contrast, lebrikizumab and tralokinumab, both act-
ing on the IL-13 pathway, have shown less consistent ef-
fects on exacerbation rates. Hanania et al. demonstrated
the inability of lebrikizumab to consistently reduce
exacerbation rates [34], this was also confirmed for tra-
lokinumab by a phase II and a phase III trial [35, 59].
GSK679586, also acting on the IL-13 pathway, was only
investigated by a phase II trial. It also had no effect on
exacerbation rates, lung function, symptom control and
health-related quality of life [62]. This may reflect the
lack of clinical effect of targeting the IL-13 pathway
alone. In a recent review, Parulekar et al. suggested that
simultaneous targeting of both IL-13 and IL-4 pathways
may benefit patients with severe asthma [70]. This the-
ory is supported by a dupilumab efficacy trial where ex-
acerbations were reduced by about 50% [19]. Biweekly
administered dupilumab also improved lung function,
symptom control and health-related quality of life [19].
It is plausible that in coming updates of leading guide-
lines dupilumab will be recommended as potential add-
on treatment in severe asthma [19]. MEDI-528, acting
on IL-9, was investigated by a phase II trial where
exacerbation rates, lung function, symptom control and
health-related quality of life are not affected by this
intervention [20]. Tezepelumab efficacy was also only in-
vestigated by a phase II trial, exacerbation rates were de-
creased with about 60 to 80% and lung function is
improved irrespective of the administered dose. Symp-
tom control was improved by medium and high dose
tezepelumab. Only the high dose improved the health-
related quality of life [13]. Those results suggest that
TSLP may also be an important drug target in asthma.
Phase III trials confirming or disproving the efficacy of
tezepelumab are still awaited [13].
Our network meta-analysis demonstrated that none of
the studied monoclonal antibodies showed statistically
significant improvement of the exacerbation rate com-
pared to the pooled placebo, nor was any treatment arm
superior in the indirect head to head comparisons. Most
studies were on mepolizumab or benralizumab. Studies
on benralizumab and lebrikizumab included the highest
number of patients and were therefore most powered
to approach statistical significance for the modest
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improvement on exacerbations compared to placebo.
The variation between the mean rates of exacerbation
rates between the pooled placebo groups and treatment
arms of IL-5 pathway versus other biologics may be
due to different inclusion criteria. It is also worth not-
ing that among the included agents, only dupilumab
and the three IL-5 pathway agents (mepolizumab, resli-
zumab and benralizumab) are currently FDA approved
for severe asthma. Mepolizumab, benralizumab and
reslizumab trials mostly included subjects based on
previous exacerbations and high number of eosinophils.
Conversely, most trials of other biologics selected subjects
based only on previous exacerbations. Effect differences in
our analyses should therefore be interpreted in light of
that difference. Since benralizumab demonstrated statisti-
cally significant reduction in the exacerbation rate com-
pared to placebo in this analysis, our results emphasize
that adequate phenotyping characterizing the underlying
endotype is key for agents targeting IL-5 to demonstrate
their efficacy. It should be of note that further high quality
trials on the included treatments and direct head to head
comparisons between the biologic agents may be needed
to fully compare between the treatment modalities inde-
pendent of patient selection differences. The difference in
the risk of bias for the studies included in the meta-ana-
lysis is also of note. For example, benralizumab had the
lowest percentage of included studies with low risk of bias,
which may have affected the positive significant effect seen
in the IL-5 pathway sub-analysis. In an earlier review of
the evidence by the Institute of Clinical and Economic Re-
view (ICER), mepolizumab was considered to be of mod-
est benefit in terms of reducing exacerbations and
improving quality of life [71]. Evidence regarding benrali-
zumab, reslizumab and dupilumab efficacy was considered
of moderate certainty, and the possibility that biologics
effects were comparable to placebo could not be ruled
out [71].
Most trials included patients based on the number of
exacerbations in the previous year, but results were more
consistent where patients had higher levels of eosino-
philia [37, 53, 54]. However, reductions in eosinophil
levels cannot infer clinical effects, as proven by lebrikizu-
mab and tralokinumab trials [34, 35, 59]. This suggests
that eosinophil levels may be used as a biomarker to select
patients predicted to benefit the most from treatment. It is
difficult however to use its post-treatment as a marker of
clinical efficacy. This was recently tested by Kelly et al.
who proved that T cells retain some functionality after
750mg doses of mepolizumab even when median values
of circulating eosinophils dropped by 75% [72]. Therefore
a reduction in eosinophil numbers cannot infer clinical
Table 3 Percentage of low risk of bias studies per treatment
arm in the meta-analysis on exacerbation rate [13, 15, 19, 33–42]
Treatment Percentage
Benralizumab 60% (3/5)
Lebrikizumab 50% (1/2)
Dupilumab 0% (0/1)
Mepolizumab 50% (1/2)
Tralokinumab 100% (1/1)
Reslizumab 100% (1/1)
Tezepelumab 100% (1/1)
Table outlining the risk of bias for different studies included in the meta-
analysis, all agents had at least 50% of low-risk studies included,
except dupilumab
Fig. 3 Exacerbation rates when treated with biologics acting on the interleukin 5 pathway [15, 36–42]. Median Annualized Exacerbation rate (95%
CI). Forest plot of the exacerbation rates among the placebo and IL-5 agent arms
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efficacy, and clinical outcomes must be used to evaluate
efficacy.
Exposure to allergens may initiate naive T-lymphocytes
differentiation towards type 2 helper T-lymphocytes (TH2
cells) in genetically susceptible individuals [73]. The aller-
gens inhalation elicits epithelial attraction of dendritic
cells, as well as epithelial production of thymic stromal
lymphopoietin (TSLP), interleukin (IL)-33 and IL-25 (pro-
TH2 co-activating cytokines). The antigen-presenting
dendritic cells migrate to the lymph nodes, where IL-4
provides the initiating stimulus for the TH polarization
towards TH2 cells. TH2 cells produce their typical TH2-as-
sociated cytokines: IL-4, IL-5, IL-9 and IL-13 [67]. Add-
itionally, innate type 2 lymphoid cells (ILC2) are a potent
source of IL-5 and IL-13. ILC2 cells may be activated by
non-allergenic or infectious stimuli [74]. Increased ILC2
numbers were associated with severe asthma with persist-
ent eosinophilia [75, 76]. IL-33 (ILC2 activator, besides
TSLP and IL-25)) was also associated to airway remodel-
ing in steroid resistant asthma [77]. IL-4 and IL-13 share a
common receptor: IL-4Rα. Both cytokines are powerful
mediators of type 2 immunity. IL-4 is the key factor in the
TH2 type response: it guides the naive T cell differentiation
to the TH2 subtype [63]. IL-4 also steers the isotype switch
of B cells towards immunoglobulin (Ig) E. The main func-
tion of IL-13 consists mediating goblet cell hyperplasia
and smooth muscle contractility. In addition, IL-13 has an
additional role in isotype class switching and IgE produc-
tion. IgE is the hallmark of allergic sensitization. It has the
potential to activate mast cells and basophils. IL-5 is the
key factor in the maturation and survival of eosinophils. It
is suggested that IL-9 mediates the mast-cell component
of the allergic reaction [47, 56]. Type 2-associated asthma
is characterized by eosinophilic airway inflammation [78].
Blood eosinophilia and FENO were the most robust
markers for this inflammation [79].
The safety profile and long term effects of those biologic
agents are also yet to be established. The adverse reactions
noted in the trials were generally limited. However, the tri-
als may have been too short or underpowered to detect
rare serious adverse events. Given possible seasonal effects
on asthma, one-year long trials are preferred instead of
shorter ones. An important example is daclizumab, re-
moved from the market in 2018 due to cases of encephal-
itis [80]. Busse et al. detected in 2008 five adverse events
in the treatment group, but a causal relationship could not
be established [68]. Two open-label extensions of mepoli-
zumab and reslizumab trials have been published [23, 24].
Overall, the drugs had a favorable side effects profile, how-
ever, there was an increased percentage of adverse events
in the treatment groups and 7% of reslizumab users expe-
rienced a serious adverse event [24]. This highlights the
importance of open-label extensions, and rigorous phar-
macovigilance when using the new biologic agents.
It is worth noting that there is a dissociation between
improved asthma outcomes and patient reported out-
comes. Having improved lung function or less exacerba-
tions does not automatically lead to better symptom
control or health-related quality of life. For example, leb-
rikizumab improved lung function but ACQ and AQLQ
were not affected. Equal observations were made for
tezepelumab. Its effect on lung function and exacerba-
tion rate was dose-independent. In contrast, ACQ only
improved in medium and high dose tezepelumab, and
Fig. 4 Exacerbation rates when treated with biologics not targeting the interleukin 5 pathway [13, 19, 33–35]. Median Annualized Exacerbation
rate (95% CI). Forest plot showing the exacerbation rates achieved with different agents targeting non-IL-5 pathways. All had wide confidence
intervals, and no statistically significant effects against placebo were detected
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AQLQ only in the high dose group. The anti-IL-5 and
anti-IL-5R biologics all significantly reduced the number
of exacerbations. However, the results about ACQ and
AQLQ were less consistent.
Biologics are considered to be expensive, emphasizing
the importance of confirming the diagnosis and asses-
sing modifiable factors, therapy compliance and inhaler
technique before their initiation. However, it remains
vital to invest in new and innovative therapeutic agents.
More adequate asthma treatment results in better symptom
control and less exacerbations and therefore with taking
less time of work, less emergency department visits and
hospitalizations. In doing so, targeted therapeutics may be
cost-effective [81]. In the ICER review, cost-effectiveness
analysis of biologic therapies in asthma (including oma-
lizumab, reslizumab, mepolizumab, benralizumab and
dupilumab) estimates did not meet commonly-cited
cost-effectiveness thresholds [71]. The subpopulations
with ≥300 eosinophil count did not change the results
substantially from the base-case as well.
Some important topics are not discussed in this re-
view. Little real-world evidence of biologics’ effectiveness
exists. The effect of biologics on top of controller ther-
apy was undiscussed. Future research should further
investigate whether controller therapy can be reduced
after disease control with biologics and whether treat-
ment with biologics could be stopped after a certain dur-
ation time.
This review primarily points out the major findings
due to difficulties comparing different trials with identi-
cal biologics, or comparing between different biologics.
This is caused by diversity in administered doses, routes
of administration, inclusion criteria and primary out-
comes. Clinical efficacy should be interpreted in light of
the selection criteria used in the trials. For example,
reslizumab seemed to obtain greater reductions in ex-
acerbation rates compared to mepolizumab and benrali-
zumab. However, this result cannot be generalized as the
leading reslizumab trial only selected patients with
higher baseline blood eosinophil counts, less exacerba-
tions in the previous year and lower controller treatment
compared to mepolizumab and benralizumab. Another
example is lebrikizumab, which only improved lung
function in patients with high serum periostin, a variable
that is not tested in other trials, therefore comparison
with other biologics is nearly impossible.
These examples demonstrate the need for further re-
finement of current described endotypes. It is clear that
some biologics are more efficacious when given to pa-
tients with elevated levels of certain biomarkers but the
threshold of these biomarkers that results in significant
improvements is not specified for any of the biologics.
Furthermore, head to head trials between different bio-
logics are necessary to make better assessments about
which biologic may be the preferred therapeutic for a
particular patient. Some agents currently in early devel-
opment phases were also not included, which may have
an important impact on asthma in the future [82].
Conclusion
In conclusion, monoclonal antibodies are promising
therapeutics for the treatment of severe, persistent
asthma. Several phase III trials demonstrated the efficacy
of mepolizumab, reslizumab and benralizumab and the
efficacy of dupilumab has been recently confirmed. Dupi-
lumab will potentially be added to the recommended bio-
logics for the treatment of severe asthma in near future.
Phase III trials that confirm or disprove the efficacy of
tezepelumab are awaited. Lebrikizumab, tralokinumab,
GSK679586 and MEDI-528 have no or inferior effects on
asthma outcome. Daclizumab improved FEV1, but was
later removed from the market due to side effects. In gen-
eral, the lack of well-defined endotypes is a major hurdle
to the interpretation and implementation of trial results.
Response is defined by observable features and bio-
markers, but no cut-off values or point of care testing are
currently available. Therefore, there are diverging inclu-
sion criteria among the several trials. Thus, endotypes
need to be further refined, and selecting severe asthma
patients based on their eosinophilia and number of ex-
acerbation appears to be a sound strategy and an import-
ant precision medicine opportunity. Head to head trials
between different biologics may be necessary to determine
the best therapeutic option for a particular patient. To
estimate and determine long-term effects, patients treated
with monoclonal antibodies should be followed up long-
term.
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